Detalles de la búsqueda
1.
Prolonged complete response to adjuvant tepotinib in a patient with newly diagnosed disseminated glioblastoma harboring mesenchymal-epithelial transition fusion.
Oncologist;
2024 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38815166
2.
Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
Jpn J Clin Oncol;
51(8): 1261-1268, 2021 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34037224
3.
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
Lancet Oncol;
13(1): 33-42, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22056021
4.
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.
Lancet Oncol;
12(1): 30-7, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21169060
5.
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
Clin Cancer Res;
28(6): 1117-1126, 2022 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34789481
6.
SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations.
iScience;
23(12): 101832, 2020 Dec 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-33305187
Resultados
1 -
6
de 6
1
Próxima >
>>